Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Looking at the evolving landscape in Wet AMD, with focus on brolucizumab, ahead of its launch in late 2019

Ticker(s): NVS, REGN

Who's the expert?

Name: Dr Sandra Montezuma - MD

Institution: University of Minnesota

  • Associate Professor in Ophthalmology at the University of Minnesota & Speaker for Novartis.
  • Treats 20-30 patients a week with Wet AMD; subspecialty expertise in providing medical and surgical care for all retina diseases in adults and children. 
  • Research interest includes translational research in Age-Related Macular Degeneration, angiogenesis, Inherited Retinal Diseases, retinal implants, and retinal prosthesis. 

Interview Questions
Q1.

  • Please tell us about your clinical practice, background in treating Wet AMD and research in the space. 
  • How many patients do you treat,what is the first line of therapy? 
  • What % of patients do not respond well?

Added By: slingshot_insights
Q2.

  • How much of a need for new treatments is there for this condition?
  • Which drugs get prescribed most often and under what specific circumstances?

Added By: slingshot_insights
Q3.

  • What are the Inflammatory Mechanisms of AMD?
  • How does Brolucizumab inhibit the activation of VEGF receptors/ block the ligand-receptor interaction?
  • Why are humanized single-chain antibody fragment (scFv) attractive candidates for targeted immunotherapy?

Added By: slingshot_insights
Q4.

What experience do you have with Topical bromfenac and intravitreal triamcinolone in conjunction with anti-VEGF intravitreal injections? Pros and cons?

Added By: slingshot_insights
Q5.

  • In the two-year HAWK and HARRIER study, brolucizumab demonstrated non-inferiority versus Eylea (aflibercept) in best-corrected visual acuity, and exhibited superiority in key retinal outcomes at 48 weeks and superiority at 96 weeks in the reduction of retinal fluid and reductions in central subfield thickness. [24% for brolucizumab 6 mg vs. 37% for aflibercept in HAWK; 24% vs. 39%, respectively, in HARRIER] 
  • Given those results, how likely would you be to switch your patients to brolucizumab after approval?

Added By: slingshot_insights
Q6.

  • Absolute reductions in CST from baseline were -175 µm for brolucizumab 6 mg vs -149 µm for aflibercept in HAWK and -198 µm versus -155 µm in HARRIER. 
  • How much would those numbers translate to an improvement on the patients’ outcomes?

Added By: slingshot_insights
Q7.

How popular has Eylea become in clinicians' offices due to its 8-week dosing regimen, since its approval in 2018?

Added By: slingshot_insights
Q8.

82% of patients in HAWK and 75 percent in HARRIER Brolucizumab studies were maintained on a 12-week dosing interval in year two, after one year on a 12-week dosing interval. How does this dosing interval and stability compare to other choices you might have?

Added By: slingshot_insights
Q9.

What % of the patients usually receive Eylea (aflibercept) and what are some common reasons for which alternatives are considered instead?

Added By: slingshot_insights
Q10.

what does the doc think about the latest phase 2b trial in 366 patients from Opthea which shows that pan VEGF inhibition (also blocking also VEGF C/D) showed for the first time using the same VEGF validated pathway there can be better efficacy from a VEGF A blocker alone (brolu, eylea, lucentis) adding 3.4 letters ontop and over 6+ letters in occult lesions

Added By: user282f0563

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.